LIVER-METABOLISM DURING TREATMENT WITH ESTRADIOL AND NATURAL PROGESTERONE

被引：14

作者：

DARJ, E

AXELSSON, O

CARLSTROM, K

NILSSON, S

VONSCHOULTZ, B

机构：

[1] Department of Obstetrics and Gynecology, Uppsala University, Uppsala

[2] Karolinska Institute, Huddinge

[3] Falun Hospital, Falun

[4] Karolinska Institute, Stockholm

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1993年 / 7卷 / 02期

关键词：

ESTRADIOL; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; CERULOPLASMIN; CORTICOSTEROID BINDING GLOBULIN; LIPOPROTEIN-A;

D O I：

10.3109/09513599309152489

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum concentrations of sex hormone-binding globulin (SHBG), corticosteroid binding globulin (CBG), ceruloplasmin, lipoprotein A and liver enzymes were measured in 30 postmenopausal women treated with 2 mg micronized 17beta-estradiol daily and micronized progesterone orally in doses of 50, 100 and 200 mg daily, as progestogen supplementation. The treatment lasted for 4 months. The serum levels of SHBG and CBG increased during treatment and a weak association between progesterone dosage and CBG was observed. Levels of lipoprotein A and liver enzymes did not change. It is concluded that micronized natural progesterone is an attractive means of progestogen supplementation in postmenopausal hormone replacement therapy without any liver-related side-effects.

引用

页码：111 / 114

页数：4

共 14 条

[1]

Ottoson U.-B., Oral progesterone and estrogen/progestogen therapy, Acta Obstet. Gynecol. Scand., 127, Suppl, pp. 7-11, (1984)

[2]

von Schoultz B., Studd J., Whitehead M., Potency of different oestrogen preparations, The Menopause, (1989)

[3]

El Makhangy M.N., Wynn V., Lawrence D.M., Sex hormone binding globulin capacity as an index of oestrogenicity and andro-genicity in women on oral contraceptive steroids, Clin. Endocrinol., 10, pp. 39-45, (1979)

[4]

Laurell C.-B., Rannevik G., Comparison of plasmaprotein changes induced by dana-zol, pregnancy and estrogens, J. Clin. Endocrinol. Metabol., 49, pp. 719-725, (1979)

[5]

Bush T., Miller V., Mishell D., Effects of pharmacologic agents used during menopause: Impact on lipids and lipoproteins, Menopause: Physiology and Pharmacology, (1987)

[6]

Dahlen G., Guyton J., Attar M., Farmer J., Kautz J., Gotto A., Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography, Circulation, 74, pp. 758-765, (1986)

[7]

Hajjar K., Gavish D., Breslow J., Nachman R., Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis, Nature (London), 339, pp. 303-305, (1989)

[8]

Miles L., Fless G., Levin E., Scanu A., Plow E., A potential basis for the thrombotic risks associated with lipoprotein(a), Nature (London), 339, pp. 301-302, (1989)

[9]

Fernlund P., Gershagen S., Larsson I., Rannevik G., Radioimmunoassay of human sex hormone binding globulin: Improved radioiodina-tion procedure, Scand. J. Clin. Lab. Invest., 45, pp. 461-469, (1985)

[10]

Lapidus L., Lindstedt G., Lundberg P.A., Bengtsson C., Gredmark T., Concentration of sex hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women, Clin. Chem., 32, pp. 146-152, (1986)

← 1 2 →